Rhinofilt GmbH
Since 2010
An important feature of this device is the ability to make external clamping parts in the form of art or jewelry.
The research company Rhinofilt GmbH (Germany), led by CEO Michael Zisser, offers a mini-inhaler developed as a result of scientific research during a joint research project with the ENT clinic of the Friedrich Schiller University in Jena.
The development phase and clinical trials lasted 2 years.
This is the world’s first mini-inhaler that can be used throughout the day without disturbing breathing parameters and side effects.
In the Mini inhaler, called “Aromaklip”, various compositions can be used, which are intended for use as a prophylactic and auxiliary agent for respiratory diseases caused by viruses and bacteria, as well as for sleep disorders, headaches, nasal congestion, sinusitis, allergies, loss of smell…
A miniature device is placed in the nasal passage and allows microdosed injection of the active components of a mixture of essential oils, specially selected by RhinofiltGmbH, into the respiratory tract.

Some photos from our working days:

  1. Conference in China
  2. University of Jena
  3. Clip performance analysis setup
  4. Exhibition in Shanghai
Unique features of AromaClip
Aromaclip is unique in its properties and characteristics
Safe and convenient
Effective for daily and night use
Does not cause inconvenience when using
Diverse in composition and functionality
Compact and invisible in use
Not conducive to overdose of inhalants
Easy to use
Maximum speed of action


What's new in our method of microdosed inhalation with essential oils...

So far, all clinical studies, both by the aromagram method and other recognized methods for evaluating the effectiveness of the action of aromatic oils, have used a single exposure of a certain amount of the active substance (aromatic oil) to a bacterial or viral (viral) environment …
We call it burst impact.
Under laboratory conditions, such a method can evaluate a locally isolated environment with pathogens, which can be “neutralized” by a certain amount of active substance.
In a complex system of the human body, where the pathogen is located outside the locally isolated zone, this method cannot determine the effectiveness of the impact, since a virus is already inside a huge number of cells, constantly initiating the cell to “reproduce” its copies. In such a system, the amount and concentration of the antiviral drug must be very high over a long period of time to be effective.
We have developed a method for introducing “transportation” of microdoses of an antiviral agent, which, over a relatively long period, constantly affects the viral environment without significantly negatively affecting the immune and other vital systems of the body.